Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.
Department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
J Leukoc Biol. 2021 Jan;109(1):49-53. doi: 10.1002/JLB.5COVR0620-306R. Epub 2020 Jul 8.
Bruton's tyrosine kinase (BTK) signaling is involved in innate immune responses and regulates the production of proinflammatory cytokines that can contribute to COVID-19 immunopathology. Clinical trials with BTK inhibitors in COVID-19 treatment have been proposed, and previous studies have attempted to investigate the therapeutic effects of ibrutinib and underlying mechanisms in treating viral pneumonia. These attempts, however, did not consider potential off target effect of BTK inhibitors on T cell differentiation, function, and survival, which may be beneficial in treatment for COVID-19. Here, we summarize the current knowledge of BTK/IL-2-inducible T-cell kinase (ITK) signaling in immunopathology and lymphopenia and discuss the potential of BTK/ITK dual inhibitors such as ibrutinib in modulating immunopathology and lymphopenia, for COVID-19 therapy.
布鲁顿酪氨酸激酶（BTK）信号参与固有免疫反应，并调节促炎细胞因子的产生，而这些细胞因子可能导致 COVID-19 免疫病理学。已经提出了用 BTK 抑制剂治疗 COVID-19 的临床试验，并且先前的研究试图研究伊布替尼在治疗病毒性肺炎中的治疗效果和潜在机制。然而，这些尝试没有考虑 BTK 抑制剂对 T 细胞分化、功能和存活的潜在脱靶效应，这可能有益于 COVID-19 的治疗。在这里，我们总结了 BTK/白细胞介素 2 诱导的 T 细胞激酶（ITK）信号在免疫病理学和淋巴细胞减少症中的现有知识，并讨论了伊布替尼等 BTK/ITK 双重抑制剂在调节 COVID-19 治疗中的免疫病理学和淋巴细胞减少症方面的潜力。
